Cogent Biosciences (COGT) Total Liabilities (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Total Liabilities of $295.3 million for Q1 2026, up 355.71% year-over-year from $64.8 million in Q1 2025, and down 1.97% quarter-over-quarter from $301.2 million in Q4 2025.
Cogent Biosciences (COGT) Total Liabilities (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Total Liabilities for 10 consecutive years, with $295.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 355.71% year-over-year to $295.3 million; the TTM figure through Mar 2026 stood at $295.3 million (up 355.71% YoY), while the FY2025 annual figure was $301.2 million, up 320.65% from the prior year.
- Total Liabilities retreated to $295.3 million in Q1 2026 per COGT's latest filing, from $301.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $301.2 million in Q4 2025 and bottomed at $19.0 million in Q1 2022.
- Historically, Total Liabilities has averaged $88.2 million across 5 years, with a median of $55.6 million in 2023.
- Annual changes were most pronounced in 2023 — Total Liabilities decreased 5.84% — and 2026, when it surged 355.71%.
- Cogent Biosciences' Total Liabilities stood at $45.1 million in 2022, then climbed by 23.43% to $55.6 million in 2023, then climbed by 28.72% to $71.6 million in 2024, then surged by 320.65% to $301.2 million in 2025, then decreased by 1.97% to $295.3 million in 2026.
- Business Quant data shows COGT's Total Liabilities at $295.3 million in Q1 2026, $301.2 million in Q4 2025, and $123.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 302.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 302.16 Mn |
| Mar 31, 2026 | 295.31 Mn |
| Dec 31, 2025 | 301.24 Mn |
| Sep 30, 2025 | 123.47 Mn |
| Jun 30, 2025 | 119.78 Mn |
| Mar 31, 2025 | 64.80 Mn |
| Dec 31, 2024 | 71.61 Mn |
| Sep 30, 2024 | 69.36 Mn |
| Jun 30, 2024 | 56.71 Mn |
| Mar 31, 2024 | 53.78 Mn |
| Dec 31, 2023 | 55.64 Mn |
| Sep 30, 2023 | 52.55 Mn |
| Jun 30, 2023 | 43.94 Mn |
| Mar 31, 2023 | 39.64 Mn |
| Dec 31, 2022 | 45.08 Mn |
| Sep 30, 2022 | 41.62 Mn |
| Jun 30, 2022 | 46.67 Mn |
| Mar 31, 2022 | 19.01 Mn |
| Dec 31, 2021 | 17.91 Mn |
| Sep 30, 2021 | 18.15 Mn |